Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas

Griffin, 1987, Predictors of survival after curative resection of carcinoma of the colon and rectum, Cancer, 60, 2318, 10.1002/1097-0142(19871101)60:9<2318::AID-CNCR2820600934>3.0.CO;2-B Gryfe, 2000, Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer, N Engl J Med, 342, 69, 10.1056/NEJM200001133420201 Compton, 2000, American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group, Cancer, 88, 1739, 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T Aarnio, 1998, Prognosis of colorectal cancer varies in different high-risk conditions, Ann Med, 30, 75, 10.3109/07853899808999387 Sankila, 1996, Better survival rates in patients with MLH1-associated hereditary colorectal cancer, Gastroenterology, 110, 682, 10.1053/gast.1996.v110.pm8608876 Halling, 1999, Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers, J Natl Cancer Inst, 91, 1295, 10.1093/jnci/91.15.1295 Karran, 1996, Microsatellite instability and DNA mismatch repair in human cancer, Cancer Biol, 7, 15, 10.1006/scbi.1996.0003 Arnheim, 1997, DNA mismatch repair in mammals: role in disease and meiosis, Curr Opin Genet Dev, 7, 364, 10.1016/S0959-437X(97)80150-5 Aaltonen, 1993, Clues to the pathogenesis of familial colorectal cancer [see comments], Science, 260, 812, 10.1126/science.8484121 Thibodeau, 1993, Microsatellite instability in cancer of the proximal colon, Science, 260, 816, 10.1126/science.8484122 Dietmaier, 1997, Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression, Cancer Res, 57, 4749 Hanford, 1998, Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair, Oncogene, 16, 2389, 10.1038/sj.onc.1201751 Thibodeau, 1998, Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1, Cancer Res, 58, 1713 Baudhuin, 2005, Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome, Fam Cancer, 4, 255, 10.1007/s10689-004-1447-6 Myrhoj, 1997, Hereditary non-polyposis colorectal cancer: clinical features and survival, Scand J Gastroenterol, 32, 572, 10.3109/00365529709025102 Samowitz, 2001, Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level, Cancer Epidemiol Biomarkers Prev, 10, 917 Jass, 2007, Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, Histopathology, 50, 113, 10.1111/j.1365-2559.2006.02549.x Nosho, 2008, Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample, PLoS One, 3, e3698, 10.1371/journal.pone.0003698 Kim, 1994, Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences, Am J Pathol, 145, 148 de la Chapelle, 2004, Genetic predisposition to colorectal cancer, Nat Rev Cancer, 4, 769, 10.1038/nrc1453 Vasen, 1991, The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC), Dis Colon Rectum, 34, 424, 10.1007/BF02053699 Lynch, 1993, Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an update review, Gastroenterology, 104, 1535, 10.1016/0016-5085(93)90368-M Rossi, 1996, National Cancer Institute workshop on genetic screening for colorectal cancer, J Natl Cancer Inst, 88, 331, 10.1093/jnci/88.6.331 Aaltonen, 1998, Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease [see comments], N Engl J Med, 338, 1481, 10.1056/NEJM199805213382101 Cunningham, 2001, The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas, Am J Hum Genet, 69, 780, 10.1086/323658 Southey, 2001, Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis, Am J Surg Pathol, 25, 936, 10.1097/00000478-200107000-00013 Watson, 1998, Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members, Cancer, 83, 259, 10.1002/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L Popat, 2005, Systematic review of microsatellite instability and colorectal cancer prognosis, J Clin Oncol, 23, 609, 10.1200/JCO.2005.01.086 Benatti, 2005, Microsatellite instability and colorectal cancer prognosis, Clin Cancer Res, 11, 8332, 10.1158/1078-0432.CCR-05-1030 Lanza, 2006, Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients, J Clin Oncol, 24, 2359, 10.1200/JCO.2005.03.2433 Wright, 2000, Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer, Br J Surg, 87, 1197, 10.1046/j.1365-2168.2000.01508.x Ribic, 2003, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med, 349, 247, 10.1056/NEJMoa022289 Carethers, 2004, Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer, Gastroenterology, 126, 394, 10.1053/j.gastro.2003.12.023 de Vos, 2004, Survival after adjuvant 5-FU treatment for stage III colon cancer in HNPCC CRC, Int J Cancer, 109, 468, 10.1002/ijc.11712 Jover, 2006, Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer, Gut, 55, 848, 10.1136/gut.2005.073015 Sargent, 2010, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, 28, 3219, 10.1200/JCO.2009.27.1825 Sinicrope, 2010, DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer, Nat Rev Clin Oncol, 7, 174, 10.1038/nrclinonc.2009.235 Siegel, 2011, Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths, CA Cancer J Clin, 61, 212, 10.3322/caac.20121 2009, Berg: Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives, Genet Med, 11, 35, 10.1097/GIM.0b013e31818fa2ff Samowitz, 2005, Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer, Gastroenterology, 129, 837, 10.1053/j.gastro.2005.06.020 de Vogel, 2009, MGMT and MLH1 promoter methylation versus APC, Ann Oncol, 20, 1216, 10.1093/annonc/mdn782 Barault, 2008, Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases, Cancer Res, 68, 8541, 10.1158/0008-5472.CAN-08-1171 English, 2008, Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype, Cancer Epidemiol Biomarkers Prev, 17, 1774, 10.1158/1055-9965.EPI-08-0091 Campbell PT, Jacobs ET, Ulrich CM, Figueiredo JC, Poynter JN, McLaughlin JR, Haile RW, Jacobs EJ, Newcomb PA, Potter JD, Le Marchand L, Green RC, Parfrey P, Younghusband HB, Cotterchio M, Gallinger S, Jenkins MA, Hopper JL, Baron JA, Thibodeau SN, Lindor NM, Limburg PJ, Martinez ME: Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst 102:391–400 Snover, 2011, Update on the serrated pathway to colorectal carcinoma, Hum Pathol, 42, 1, 10.1016/j.humpath.2010.06.002 Kane, 1997, Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines, Cancer Res, 57, 808 Herman, 1998, Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma, Proc Natl Acad Sci U S A, 95, 6870, 10.1073/pnas.95.12.6870 Cunningham, 1998, Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability, Cancer Res, 58, 3455 Kuismanen, 2000, Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers, Am J Pathol, 156, 1773, 10.1016/S0002-9440(10)65048-1 Samowitz, 2007, The CpG island methylator phenotype in colorectal cancer, J Mol Diagn, 10.2353/jmoldx.2007.070031 Ogino, 2007, Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample, J Mol Diagn, 9, 305, 10.2353/jmoldx.2007.060170 Oliveira, 2004, Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status, Hum Mol Genet, 13, 2303, 10.1093/hmg/ddh238 Menigatti, 2001, Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer, Genes Chromosomes Cancer, 31, 357, 10.1002/gcc.1154 McGivern, 2004, Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer, Fam Cancer, 3, 101, 10.1023/B:FAME.0000039861.30651.c8 Young, 2001, Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis, Am J Pathol, 159, 2107, 10.1016/S0002-9440(10)63062-3 Rahner, 2008, Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome, J Pathol, 214, 10, 10.1002/path.2263 Morak, 2008, Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC, Eur J Hum Genet, 16, 804, 10.1038/ejhg.2008.25 Niessen, 2009, Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome, Genes Chromosomes Cancer, 48, 737, 10.1002/gcc.20678 Toyota, 1999, Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification, Cancer Res, 59, 2307 Toyota, 1999, CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci U S A, 96, 8681, 10.1073/pnas.96.15.8681 Sepulveda, 2009, CpG methylation analysis–current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology, J Mol Diagn, 11, 266, 10.2353/jmoldx.2009.080125 Teodoridis, 2008, CpG island methylator phenotype (CIMP) in cancer: causes and implications, Cancer Lett, 268, 177, 10.1016/j.canlet.2008.03.022 Ogino, 2008, Molecular classification and correlates in colorectal cancer, J Mol Diagn, 10, 13, 10.2353/jmoldx.2008.070082 Linhart, 2007, Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing, Genes Dev, 21, 3110, 10.1101/gad.1594007 Nosho, 2009, DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer, Clin Cancer Res, 15, 3663, 10.1158/1078-0432.CCR-08-2383 Kambara, 2004, BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum, Gut, 53, 1137, 10.1136/gut.2003.037671 Jass, 2005, Serrated adenoma of the colorectum and the DNA-methylator phenotype, Nat Clin Pract Oncol, 2, 398, 10.1038/ncponc0248 Ogino, 2009, CpG island methylator phenotype, microsatellite instability: BRAF mutation and clinical outcome in colon cancer, Gut, 58, 90, 10.1136/gut.2008.155473 Domingo, 2004, BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing, J Med Genet, 41, 664, 10.1136/jmg.2004.020651 Koinuma, 2004, Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas, Int J Cancer, 108, 237, 10.1002/ijc.11523 Halvarsson, 2008, Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers, Am J Clin Pathol, 129, 238, 10.1309/0PP5GDRTXUDVKAWJ Rajagopalan, 2002, Tumorigenesis: rAF/RAS oncogenes and mismatch-repair status, Nature, 418, 934, 10.1038/418934a Deng, 2004, BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer, Clin Cancer Res, 10, 191, 10.1158/1078-0432.CCR-1118-3 Domingo, 2005, BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes, Oncogene, 24, 3995, 10.1038/sj.onc.1208569 Bessa, 2008, A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening, Clin Gastroenterol Hepatol, 6, 206, 10.1016/j.cgh.2007.10.011 Nakagawa, 2009, Efficient molecular screening of Lynch syndrome by specific 3′ promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability, Oncol Rep, 21, 1577 O'Brien, 2006, Comparison of microsatellite instability: CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points, Am J Surg Pathol, 30, 1491, 10.1097/01.pas.0000213313.36306.85 Minoo, 2006, Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis, Gut, 55, 1467, 10.1136/gut.2005.082859 Tanaka, 2010, Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer, Am J Pathol, 177, 2731, 10.2353/ajpath.2010.100361 Hinoue, 2009, Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling, PLoS One, 4, e8357, 10.1371/journal.pone.0008357 Weisenberger, 2006, CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, Nat Genet, 38, 787, 10.1038/ng1834 Lynch, 2003, Hereditary colorectal cancer, N Engl J Med, 348, 919, 10.1056/NEJMra012242 Barnetson, 2006, Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer, N Engl J Med, 354, 2751, 10.1056/NEJMoa053493 Vasen, 2007, Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer), J Med Genet, 44, 353, 10.1136/jmg.2007.048991 Palomaki, 2009, EGAPP supplementary evidence review: dNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome, Genet Med, 11, 42, 10.1097/GIM.0b013e31818fa2db Wijnen, 1998, MSH2 genomic deletions are a frequent cause of HNPCC, Nat Genet, 20, 326, 10.1038/3795 Taylor, 2003, Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA, Hum Mutat, 22, 428, 10.1002/humu.10291 Kastrinos, 2008, Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States, Cancer Epidemiol Biomarkers Prev, 17, 2044, 10.1158/1055-9965.EPI-08-0301 de Jong, 2006, What is the appropriate screening protocol in Lynch syndrome?, Fam Cancer, 5, 373, 10.1007/s10689-006-0008-6 Aarnio, 1995, Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome, Int J Cancer, 64, 430, 10.1002/ijc.2910640613 Barrow, 2008, Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution: A report of 121 families with proven mutations, Clin Genet, 74, 233, 10.1111/j.1399-0004.2008.01035.x Bonadona, 2011, Cancer risks associated with germline mutations in MLH1, JAMA, 305, 2304, 10.1001/jama.2011.743 Salovaara, 2000, Population-based molecular detection of hereditary nonpolyposis colorectal cancer, J Clin Oncol, 18, 2193, 10.1200/JCO.2000.18.11.2193 Tuupanen, 2007, No evidence for dual role of loss of heterozygosity in hereditary non-polyposis colorectal cancer, Oncogene, 26, 2513, 10.1038/sj.onc.1210038 Engel, 2006, Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer, Int J Cancer, 118, 115, 10.1002/ijc.21313 Ollila, 2008, Mechanisms of pathogenicity in human MSH2 missense mutants, Hum Mutat, 29, 1355, 10.1002/humu.20893 Overbeek, 2008, Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting, Am J Surg Pathol, 32, 1246, 10.1097/PAS.0b013e31816401bb Shia, 2008, Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome, part I: The utility of immunohistochemistry, J Mol Diagn, 10, 293, 10.2353/jmoldx.2008.080031 Jarvinen, 2009, Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members, J Clin Oncol, 27, 4793, 10.1200/JCO.2009.23.7784 Vasen, 1998, A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers, Cancer, 82, 1632, 10.1002/(SICI)1097-0142(19980501)82:9<1632::AID-CNCR6>3.0.CO;2-C Jarvinen, 2000, Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer, Gastroenterology, 118, 829, 10.1016/S0016-5085(00)70168-5 Shia, 2009, Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel, Am J Surg Pathol, 33, 1639, 10.1097/PAS.0b013e3181b15aa2 Goel, 2003, Characterization of sporadic colon cancer by patterns of genomic instability, Cancer Res, 63, 1608 Woerner, 2003, Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes, Oncogene, 22, 2226, 10.1038/sj.onc.1206421 Iino, 1999, DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer?, J Clin Pathol, 52, 5, 10.1136/jcp.52.1.5 Iino, 2000, DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer, Gut, 47, 37, 10.1136/gut.47.1.37 Gologan, 2005, Performance of the revised Bethesda guidelines for identification of colorectal carcinomas with a high level of microsatellite instability, Arch Pathol Lab Med, 129, 1390, 10.5858/2005-129-1390-POTRBG Greenson, 2009, Pathologic predictors of microsatellite instability in colorectal cancer, Am J Surg Pathol, 33, 126, 10.1097/PAS.0b013e31817ec2b1 Schwitalle, 2008, Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers, Gastroenterology, 134, 988, 10.1053/j.gastro.2008.01.015 Speetjens, 2008, Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers, Gastroenterology, 135, 711, 10.1053/j.gastro.2008.04.040 Lee, 2008, Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation, Pathol Int, 58, 104, 10.1111/j.1440-1827.2007.02197.x Kim, 2009, Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers, Virchows Arch, 455, 485, 10.1007/s00428-009-0857-0 Samowitz, 2005, Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers, Cancer Res, 65, 6063, 10.1158/0008-5472.CAN-05-0404 Dahlin, 2010, The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status, Clin Cancer Res, 16, 1845, 10.1158/1078-0432.CCR-09-2594 Jenkins, 2007, Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study, Gastroenterology, 133, 48, 10.1053/j.gastro.2007.04.044 Hampel, 2005, Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer), N Engl J Med, 352, 1851, 10.1056/NEJMoa043146 Debniak, 2000, Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer, Eur J Cancer, 36, 49, 10.1016/S0959-8049(99)00208-7 Pinol, 2005, Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer, JAMA, 293, 1986, 10.1001/jama.293.16.1986 Cicek, 2011, Quality assessment and correlation of MSI and IHC markers among population- and clinic-based colorectal tumors, J Mol Diagn, 13, 271, 10.1016/j.jmoldx.2010.12.004 Vasen, 1999, New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC Lynch syndrome) proposed by the International Collaborative Group on HNPCC, Gastroenterology, 116, 1453, 10.1016/S0016-5085(99)70510-X Southey, 2005, Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer, J Clin Oncol, 23, 6524, 10.1200/JCO.2005.04.671 Umar, 2004, Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst, 96, 261, 10.1093/jnci/djh034 Bansal, 2011, Efficient and cost effective population resequencing by pooling and in-solution hybridization, PLoS One, 6, e18353, 10.1371/journal.pone.0018353 Mvundura, 2010, The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer, Genet Med, 12, 93, 10.1097/GIM.0b013e3181cd666c 2010 Rex, 2009, American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected], Am J Gastroenterol, 104, 739, 10.1038/ajg.2009.104 Lindor, 2006, Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review, JAMA, 296, 1507, 10.1001/jama.296.12.1507 Gatalica, 2008, Pathology of the hereditary colorectal carcinoma, Fam Cancer, 7, 15, 10.1007/s10689-007-9146-8 Ladabaum, 2011, Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis, Ann Intern Med, 155, 69, 10.7326/0003-4819-155-2-201107190-00002